Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EPISTENT

This article was originally published in The Gray Sheet

Executive Summary

One year angiographic substudy results show up to a 60% decrease in mortality for patients randomized to stent placement plus abciximab over patients randomized to stent plus placebo or angioplasty with abciximab, reports Michael Lincoff, MD, Cleveland Clinic, at a Nov. 9 AHA press conference. Commenting on the 900-patient substudy, Lincoff noted: "Mortality is generally something we don't see a significant difference in trials this size because unfortunately death occurs frequently in this population of patients." The substudy hoped to cover as broad a clinical population as possible, he noted. Lincoff reported statistically significant mortality results of 2.4% for the placebo+stent group, 2.1% for the angioplasty+abciximab group, and 1.0% in stent +abciximab group

You may also be interested in...



QUOTED. 26 November 2020. Rachel Nuzum.

Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.

China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel